Roquefort Therapeutics complete the Acquisition of Oncogeni Limited, Placing and Admission
September 2022
Roquefort Therapeutics, the Main Market listed biotech company focused on developing first-in-class drugs in the high-value and high-growth oncology segment, has completed the acquisition of the entire issued share capital of Oncogeni Limited for an aggregate consideration of £5,500,000 satisfied by the issue of 50,000,000 new ordinary shares in the Company to the shareholders of Oncogeni.
This included the admission of the 57,249,998 new Ordinary Shares, comprising the 50,000,000 Consideration Shares and 7,249,998 Placing Shares of £0.01 each, to the Official List.
Admission to the Official List and First Day of Dealings
Admission and the first day of dealings commenced on 16th September 2022.
Having previously helped Roquefort Therapeutics with the production of their Initial Public Offering Admission Document in March 2021, and subsequently, with their Acquisition of Lyramid Pty Limited and Placing in December 2021, the Perivan shareholder communications team was delighted to again be involved with the production of the 100-page prospectus for this next stage of their corporate journey.
For further information click here.
Perivan specialise in producing and publishing financial documents relating to shareholder and investor communications for quoted companies, private companies, and open and closed-ended funds.
